Drugs / 177Lu-PSMA-VG01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07660211 | Jun 2026 → May 2027 expected | castration-resistant prostate carcinoma | VitsGen Therapeutics Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-18 | VitsGen Therapeutics Inc. | VitsGen’s IND for Novel PSMA-Targeting Radioligand Therapy (177Lu-PSMA-VG01) in mCRPC Accepted by China’s CDE vitsgen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-PSMA-VG01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07660211 ↗ |
| Route | Intravenous | “treated with 177Lu-PSMA-VG01 injection intravenously” NCT07660211 ↗ |